RANDOMIZED TRIAL
Infant protection
A prospective randomized field trial in Finland evaluated the protective efficacy of a PRP-protein conjugate vaccine against invasive Hib disease.
READ STUDY ↗
VACCINE PROFILE / CAPSULAR CONJUGATES
Hib
Vaccines.
Discover how protein-conjugated capsular polysaccharide antigens generate protective immune responses against Haemophilus influenzae type b and its invasive infections.
EXPLORE THE MOLECULAR MECHANISM ↗
FIG 01 / HIB CAPSULAR ANTIGEN
Original schematic of an encapsulated Hib bacterium
01 / PATHOGEN BIOLOGY
A capsule with
clinical significance.
Haemophilus influenzae type b (Hib) is an encapsulated Gram-negative bacterium capable of causing invasive infections, including meningitis.
Its type b capsule contains polyribosylribitol phosphate (PRP), a polysaccharide that is a key target of protective antibodies.
Scientific distinction:
Hib vaccination targets type b
disease. It does not provide
comprehensive protection against
other encapsulated or nonencapsulated
H. influenzae strains.
02 / IMMUNOLOGICAL MECHANISM
Why conjugation matters.
Hib conjugate vaccines link the PRP polysaccharide to a protein carrier, enabling stronger T-cell-dependent responses than unconjugated polysaccharide alone in young children.
01
PRP antigen
The capsular polysaccharide provides type b-specific antibody targets.
02
Protein carrier
Carrier-protein peptides support T-cell help following antigen processing and presentation.
03
Anti-PRP antibodies
The immune response generates antibodies that recognize the Hib capsule.
04
Immune memory
Conjugation supports memory responses important for sustained protection.
03 / CLINICAL RESEARCH
A major achievement
in childhood vaccination.
Clinical trials and population surveillance provide substantial evidence that Hib conjugate vaccination reduces invasive type b disease and meningitis.
POPULATION SURVEILLANCE
Impact in England
Enhanced surveillance documented a major reduction in invasive Hib disease in young children following routine conjugate vaccination.
READ STUDY ↗MENINGITIS SURVEILLANCE
Long-term program impact
Population-based surveillance in Mongolia investigated the effect of Hib conjugate vaccine introduction on childhood meningitis.
READ STUDY ↗
04 / VACCINE FORMULATION
One antigen.
Different carriers.
Hib conjugate vaccines share the PRP antigen but may differ in their protein carrier and combination-vaccine formulation.
PRP-T
PRP capsular polysaccharide conjugated to tetanus toxoid.
PRP-OMP
PRP conjugated to an outer-membrane protein complex.
Combination vaccines
Hib antigens may be incorporated into combination childhood vaccines, depending on the licensed formulation.
05 / SCIENTIFIC ANSWERS
Hib vaccine
essentials.
What does a Hib vaccine prevent?
Hib vaccines help prevent invasive disease caused by Haemophilus influenzae type b, including Hib meningitis.
What is PRP in Hib vaccines?
PRP is polyribosylribitol phosphate, the type b capsular polysaccharide used as a vaccine antigen.
Do Hib vaccines prevent influenza?
No. Despite its name, Haemophilus influenzae is a bacterium. Hib vaccines do not protect against influenza viruses.
06 / SCIENTIFIC REFERENCES
Research and guidance.
- Randomized field trial of a Hib conjugate vaccine in Finland.
- Impact of Hib conjugate vaccines in England.
- Population surveillance of Hib vaccine impact in Mongolia.
- CDC — Types of Hib Vaccines.
- WHO — Hib Vaccine Position Papers.
Educational scientific information. Vaccination decisions and schedules should follow professional advice and current regional recommendations.
NEXT / VACCINE ATLAS 10
MenABCWY Vaccines
Explore pentavalent meningococcal vaccine design and combined serogroup coverage.